News & Updates
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Interested in learning more about Hyfe? Read about all of our news, announcements and updates here!
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.
Hyfe’s AI-powered cough monitoring is now available on Actigraph’s FDA-cleared LEAP wearable, enabling continuous, privacy-preserving cough tracking alongside key health biomarkers
Clinical Trial Results Demonstrate Alkaline Magnesium-Based Salt Aerosol Reduced Cough Frequency by up to 35% in Refractory Chronic Cough Patients with Cough Counts Measured Continuously by AI-Powered tech
Hyfe's cough tracker was used in study by University of Navarra, revealing significant variability in cough patterns. This breakthrough highlights potential for continuous, objective chronic cough monitoring.
CoughPro app introduces the world’s first digital Cough Management feature, offering AI-driven solutions for millions suffering from chronic cough.
Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.
AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.
Hyfe's technology integrated into ActiGraph’s new FDA-cleared LEAP wearable device that will advance the use of remote patient monitoring in chronic cough clinical research.
Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Hyfe is expanding into chronic cough treatment with the world's first digital therapeutic for cough, using a proprietary model that combines real time cough frequency with cough suppression therapy.
150 winners selected out of 13,000 private companies; Hyfe recognized for contributions in screening, monitoring and diagnostics technologies
Hyfe has entered into an agreement with Merck, to integrate its artificial intelligence-powered (AI) cough tracker technology into Merck’s consumer disease educational efforts.
Leader in acoustic epidemiology empowers health care providers, researchers, pharmaceutical companies, and patients with cough detection and classification platform
Scientists use Hyfe to confirm that continuous cough monitoring for Long COVID was more sensitive in evaluating cough variability and response to treatment compared to patient reported outcomes.
Dr. Peter Small, Hyfe Chief Medical Officer has delivered deliver an intervention to the G20 Meeting in Yogyakarta, Indonesia, on the role of digital innovation in addressing public health crises.
With apps and artificial intelligence, researchers want to use the cough to better diagnose asthma, Covid-19 and other respiratory illnesses
Accomplished physician, scientist, and product developer to lead Hyfe's efforts as it seeks to transform patient care through cough monitoring and diagnosis.
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough
Wilmington, Del., October 16, 2025 – Hyfe, Inc., the global leader in AI-powered cough care, today announces results from a proof-of-concept study demonstrating that its digital therapeutic (DTx) produced clinically meaningful improvements in patients with refractory and unexplained chronic cough (RCC/UCC). Evidence shows Behavioral Cough Suppression Therapy (BCST), typically delivered in-person by speech-language pathologists, is highly effective at helping patients address and reduce their urge to cough, but access is limited. Fewer than 200 therapists in the U.S. offer BCST, leaving most of the six million people with RCC/UCC without effective options.
These findings mark an important step toward expanding non-drug treatment options for chronic cough, a persistent and often debilitating condition with few effective therapies available. RCC and UCC affect up to 10% of adults globally, yet there are currently no FDA-approved medications to effectively treat it. The study will be presented in the breaking news section at the leading pulmonary and critical care medicine conference, CHEST 2025, on Thursday, October 21 in Chicago, Illinois.
The single-cohort proof-of-concept study (N=10 with RCC) evaluated the DTx over a four-week treatment period. Cough frequency and bouts were monitored using the app, and quality of life was measured using the Leicester Cough Questionnaire (LCQ). Across all participants, average cough frequency fell by 41.8% and cough bouts by 41.5%. The results were stronger still for those with more severe coughs (more than 10 coughs per hour), with a reduction of 43.9% and 44.2% in coughs and bouts, respectively. Additionally, 80% of participants reported clinically meaningful improvement in quality of life.
To expand access, Hyfe integrated key elements of BCST directly into its CoughPro wellness monitoring app, creating a tool that delivers BCST-based guidance through a smartphone. Through the program, patients receive education about cough hypersensitivity and step-by-step training modules in cough suppression techniques, paired with Hyfe's AI-driven cough monitoring technology to track progress in real time. The same AI algorithms, validated across more than 50 clinical studies, enable accurate, continuous cough tracking for patients and clinicians to objectively measure improvement.
These findings mark an important step toward expanding access to proven cough therapies through digital innovation in the U.S. and globally. By digitizing behavioral cough suppression, these research findings are a critical step in bridging the gap between research and real-world accessibility. With global pharmaceutical leaders like KYORIN Pharmaceutical Co. launching this treatment exclusively in Japan, we hope further partnerships will bring this solution to more patients in additional markets worldwide.
Dr. Peter Small
Chief Medical Officer at Hyfe
The results provide evidence for the effectiveness of DTx for Behavior Cough Suppression Therapy and highlight the future potential of app-based behavioral care to meet needs that traditional treatment and BCST are missing.
To explore partnership opportunities or learn more about Hyfe’s digital therapeutic platform, visit hyfe.com or schedule a call here.
Hyfe, Inc. is the global leader in AI-powered cough-monitoring technology. The company’s patented machine-learning software enables passive, long-term monitoring of cough frequency, revealing novel health insights. Hyfe delivers cough-monitoring solutions that empower pharma and academic researchers to advance clinical trials, enable healthcare providers to optimize patient care, and power digital therapeutics to transform the management of respiratory illness, including chronic cough. Hyfe’s technology has been used in 50+ research studies, and its long-term partners include global pharma companies and leading academic institutions. More information is available at hyfe.com.
###
Media contact:
press@hyfe.com
Comprehensive Chronic Cough Report reveals $15B opportunity. 100M patients, zero FDA-approved drugs, positioning digital cough monitoring as essential pharma infrastructure.
Review including Hyfe research evaluates continuous digital cough monitoring as a practical way to address limitations of patient-reported cough data
Study results demonstrate digital Behavioral Cough Suppression Therapy reduced cough frequency by over 40% in patients with refractory and unexplained chronic cough.
Strategic partnership with KYORIN Pharmaceuticals aims to improve outcomes and expand treatment access to millions impacted by chronic cough globally.